Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IGT - Impaired Glucose Tolerance Clear all
Completed Phase 4 Interventional Results available

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

NCT01856907
View directory record Official record
Conditions
Disorder of Glucose Regulation
Interventions
Sitagliptin-Metformin, Metformin, Placebo pill
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Not applicable Interventional

Lifestyle Intervention Program for Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance

NCT01489163
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Lifestyle Counseling
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 9, 2026, 10:36 AM EDT
Recruiting Not applicable Interventional

Peanuts for Cardiometabolic, Brain, and Intestinal Health

NCT06867198
View directory record Official record
Conditions
Prediabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Cognition, Microvascular Function, Gut Microbiota, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Blood Pressure, Adult
Interventions
Peanuts
Dietary Supplement
Lead sponsor
Georgia State University
Other
Eligibility
20 Years to 59 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Not applicable Interventional Results available

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

NCT00413335
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
10 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 9, 2026, 10:36 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

NCT06967558
View directory record Official record
Conditions
PreDiabetes
Interventions
Exendin 9-39, Saline
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Phase 4 Interventional Results available

Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)

NCT00887510
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Trandolapril
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

NCT00122447
View directory record Official record
Conditions
Impaired Glucose Tolerance, Prediabetic State
Interventions
Aspirin, Alpha lipoic acid, Olmesartan, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 9, 2026, 10:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Exercise Resistance in Metabolic Disease

NCT03945435
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Not listed
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 9, 2026, 10:36 AM EDT
Recruiting Not applicable Interventional

Risk-informed Shared-decision Making Engagement Strategy for Patients With Prediabetes

NCT07553325
View directory record Official record
Conditions
Prediabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Interventions
Risk Informed Shared Decision-Making Strategy (RISE), Low Touch Messaging Strategy (LTM)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 9, 2026, 10:36 AM EDT
Active, not recruiting Phase 4 Interventional

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

NCT03938389
View directory record Official record
Conditions
PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure
Interventions
Sacubitril-Valsartan Tab 97-103 MG, Valsartan 160mg, Placebo Oral Tablet
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults

NCT00352287
View directory record Official record
Conditions
Obesity, Metabolic Syndrome, Impaired Glucose Tolerance
Interventions
Recombinant human growth hormone; pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2006 · Synced Oct 9, 2026, 10:36 AM EDT
Terminated Phase 2 Interventional Results available

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

NCT03980730
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Tucson, Arizona • New Haven, Connecticut • Atlantis, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 9, 2026, 10:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise Training and Glucose Metabolism in Aging

NCT00701051
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance (Prediabetes)
Interventions
Aerobic exercise training, Detraining (cessation of exercise)
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Phase 3 Interventional Results available

Actos Now for Prevention of Diabetes (ACT NOW)

NCT00220961
View directory record Official record
Conditions
Impaired Glucose Tolerance, Type 2 Diabetes
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 9, 2026, 10:36 AM EDT
Active, not recruiting Not applicable Interventional

Resistance Training for the Improvement of Glycemic Control in Prediabetes

NCT06697756
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Interventions
High-effort resistance exercise training, Low-effort resistance exercise training
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Meal Patterning on Weight Loss With Changes to Body Comp, Muscle and Metabolic Health

NCT02066948
View directory record Official record
Conditions
Body Composition, Beneficial, Paresis, Impaired Glucose Tolerance
Interventions
wt loss, meal pattern, even, skew
Other · Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
19 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 9, 2026, 10:36 AM EDT
Withdrawn Not applicable Interventional

Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes - Main Study

NCT03315663
View directory record Official record
Conditions
Prediabetes, Hyperglycemia, Postprandial Hyperglycemia, Impaired Glucose Tolerance, Impaired Fasting Glucose
Interventions
Sweetch App & DBWS, Sweetch App Alone
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Phase 4 Interventional Results available

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

NCT00546728
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Exenatide, Metformin
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Phase 2 Interventional

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

NCT00847899
View directory record Official record
Conditions
Hypertension, Impaired Glucose Tolerance
Interventions
AR9281, Placebo
Drug
Lead sponsor
Arete Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
30
States / cities
Mobile, Alabama • Muscle Shoals, Alabama • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 9, 2026, 10:36 AM EDT
Not listed Phase 2 Interventional

Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR

NCT01364155
View directory record Official record
Conditions
Impaired Glucose Tolerance, Insulin Resistance
Interventions
LIM-0705, Placebo capsules
Drug
Lead sponsor
Limerick BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 9, 2026, 10:36 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Growth Hormone Resistance of Beta-cells

NCT07581860
View directory record Official record
Conditions
Healthy, Obesity & Overweight, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (Prediabetes)
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 9, 2026, 10:36 AM EDT
Completed Not applicable Interventional

Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program

NCT01030978
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Bright Bodies Healthy Lifestyle Program, Control
Behavioral
Lead sponsor
Yale University
Other
Eligibility
11 Years to 16 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 9, 2026, 10:36 AM EDT
Terminated No phase listed Observational

Impaired Glucose Tolerance and Cognition in MS

NCT04748302
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 59 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 9, 2026, 10:36 AM EDT